Predictive assay for anti-angiogenic agents identifies a molecular subgroup of RAS wt mCRC with low efficacy of FOLFIRI plus bevacizumab
Predictive assay for anti-angiogenic agents (AADx) identifies a molecular subgroup of RAS wt mCRC with low efficacy of FOLFIRI plus bevacizumab – analysis of the FIRE-3 (AIO KRK-0306) trial.